NSIP, i.e., non-specific IPT pneumonia, is a chronic IMTP disease. The following is a detailed account of their treatment:
I. Diagnosis
1. Clinical performance
Respiratory system symptoms: Patients may have symptoms such as dry cough, aggravated respiratory difficulties, etc. These symptoms are a direct manifestation of the reduction of lung function as a result of pulmonary fibrosis.
Symptoms of the whole body: may be associated with reduced body weight, reduced appetite, lack of strength, etc. These symptoms reflect a decline in the overall health status of patients.
2. Visual characteristics
High resolution CT (HRCT): is an important means to diagnose lung fibrosis. The PPF may be shown on the HRCT as a double-pulmonary epidemiology, e.g. a mesh image, a change in beehive sample, tortilla bronchial extension, etc. These characterizations help doctors to make preliminary judgements on lung fibrosis.
Other video screens: for example, X-rays, although with low resolution, can also be used as a preliminary screening tool. On the chest tablets, pulmonary fibrosis may be manifested in increased pulmonary textures, disorders, linear stripe textures in the field of the pulmonary field, such as fine grid samples.
3. Lung functional examination
Hard lung activity (FVC): used to assess the size of the lung activity. PPF patients usually show a decline in FVC absolute values.
Carbon monoxide (DLCO): A gas exchange function that reflects the lung. PPF patients usually show a decline in the absolute value of the DLCO, suggesting damage to the gas exchange function of the lung.
Other lung function indicators, such as reduced lung adaptability and restricted aerobics, can also be found in PPF patients.
Organization of pathological examinations
Pulmonary biopsy: Pathological examinations conducted through the collection of tissue samples from the lung are the gold standard for determining pulmonary fibrosis. Characteristic pathologies such as glyphin deposition and fibrous cell growth in lung tissues can be observed in pulmonary activity tests.
Caution: Pulmonary biopsy is a creative examination and is determined on a trade-off basis. At the same time, pulmonary activity is not 100 per cent positive and there is a certain risk of complications.
5. Diagnostic criteria
According to the guidelines of the American Breast Science Society, the European Respiratory Society and others, PPF diagnostics are usually based on the following criteria:
Clear history and clinical performance of pulmonary fibrosis.
Breast-image screenings (e.g., HRCT) show a perplexing pathology of the lungs, which is increasing.
Pulmonary function examinations showed a decline in FVC and/or DLCO absolute values.
Pulmonary biopsy is performed when necessary to identify pulmonary fibrosis.
6. Identification diagnosis
Other chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and specific pulmonary fibrosis (IPF), need to be identified for the PPF. These diseases may be similar in terms of clinical performance, visual characteristics and lung function examination, but have their own characteristics and diagnostic criteria.
Treatment
Drug treatment
Sugar cortex hormones: NSIP reacts well to sugar cortex hormones and is expected to be good. Common drugs, such as Ponesson, require the initial treatment to be adjusted to the patient ‘ s condition and then gradually reduced to a sustained dose.
Immunosuppressants, such as cyclophosphate, sulphate, etc., can be used for assistive treatment or considered when the sugar cortex hormone is not working.
Anti-fibrosis drugs: e.g., nitoxone, although its timing and efficacy require further study, may be considered for use under certain circumstances.
General treatment
Adequate rest is guaranteed to avoid overwork.
To prevent cooling by increasing and reducing clothing in a timely manner based on temperature changes.
Keep the residential environment clean and open and ventilated, but avoid fluent winds.
More fresh fruit and vegetables, such as apples, tomatoes, etc., enhance body immunity.
Follow-up and monitoring
The NSIP patients are required to follow up regularly to assess their progress and the effectiveness of treatment.
Follow-up visits include, but are not limited to, chest CT, lung function screening, sero-immunological-related antibodies, etc.
Lifestyle interventions
Keep your mood up, don’t get too emotional.
Appropriate participation in some outdoor sports, such as walking, walking, etc., taking into account their own circumstances, while avoiding violent sports.
In the light of the above, NSIP diagnostics require a combination of clinical performance, secondary examination results and individual circumstances. Treatment is based on drug treatment, supported by general treatment and follow-up monitoring. At the same time, lifestyle interventions are an integral part of the treatment of NSIP. Patients are required to regulate treatment and management under the guidance of a doctor in order to improve their quality of life and delay their progress.
